Carmen Lefaucheur is Doctor in the Renal Transplant department in Saint-Louis Hospital

My aim is to develop a multidisciplinary approach and a translational research in organ transplantation, based on the connection of immunological, histological, molecular and clinical knowledge.

This approach will allow us to understand and identify new relevant diseases, refine diagnosis and staging of diseases and stratify the risk of graft loss. These lessons will open a new understanding of transplant failures. My research interests are focused on a major turning point in the field of transplantation, the pivotal role of the alloantibody response in clinical transplantation, the mechanisms of action of these antibodies and the development of specific therapies of antibody-mediated rejection in transplant populations.

Even if my work is focused on the human model of kidney transplantation, these notions go far beyond renal grafts and I aim to integrate information of the alloimmune response in the fields of heart and lung transplantations.

Beginning 5 yrs ago, I have worked in the Immulogy-Therapeutic Targets INSERM UMR-S-940 and Jean Dausset laboratories on the clinical relevance of anti-HLA antibodies in kidney transplantation. I have developed an important network, including national and international collaborations (Tissue Typing Laboratory, University of Pittsburgh Medical Center ; Laboratory of Transplant Applied Genomic Center. University of Alberta, Edmonton).

We constructed a national database network approved by the National French Commission for bioinformatics including seven French transplant centers (DIVAT, Données Informatisées VAlidées en Transplantation). This permitted my colleagues and I to describe new distinct and clinical relevant patterns of rejection, such as antibody-mediated vascular rejection or subclinical antibody-mediated rejection. More generally, our data support in a human model the notion of immunologic damage demonstrated in murine models.

The identification of antibody-mediated vascular rejection points out thinking toward the more general concept of vascular damage and immune accelerated arteriosclerosis. We have also provided concrete information regarding the stratification of immunological risk in kidney transplantation, post transplant specific immunossupression therapies and treatment of allograft rejections. The antibody-targeting treatment we proposed is now recognized by FDA as the gold standard therapy for antibody-mediated rejection and worldwide use in medical practice.

Derniers articles

sample

PMID: 29086461AbstractInflammation in fibrosis areas (i-IF/TA) of kidney allografts is associated with allograft loss;...

Posté par : Dr. Carmen Lefaucheur

sample

PMID: 28554738 AbstractAddressing the causes of kidney allograft-accelerated aging is an important challenge for...

Posté par : Dr. Carmen Lefaucheur

sample

PMID: 28133619AbstractThe purpose of the present review is to describe how we improve the model for risk stratification...

Posté par : Dr. Carmen Lefaucheur

sample

PMID: 27493255AbstractThe diagnosis system for allograft loss lacks accurate individual risk stratification on the basis...

Posté par : Dr. Carmen Lefaucheur

sample

PMID: 23182298 SummaryBackgroundRejection of allografts has always been the major obstacle to transplantation...

Posté par : Dr. Carmen Lefaucheur

sample

PMID: 21668626AbstractThe utilization of sensitive techniques of detection of HLA antibodies to define and measure...

Posté par : Dr. Carmen Lefaucheur

sample

PMID: 20634297AbstractThe clinical importance of preexisting HLA antibodies at the time of transplantation, identified...

Posté par : Dr. Carmen Lefaucheur

sample

PMID: 19422335AbstractDifferent strategies appear to improve the success in treatment of antibody-mediated rejection...

Posté par : Dr. Carmen Lefaucheur

sample

PMID: 26293822AbstractAntibodies may have different pathogenicities according to IgG subclass. We investigated the...

Posté par : Dr. Carmen Lefaucheur

sample

PMID: 26693703AbstractComplement inhibitors have not been thoroughly evaluated in the treatment of acute...

Posté par : Dr. Carmen Lefaucheur

Dernières actualités

2014-2017 © Copyright - Paris Transplant Group

Website by Pearlweb